

Page 76 (original), line 1, please delete "CLAIMS" and insert -- WE CLAIM: --.

IN THE CLAIMS:

- ✓ Please delete Claim 1 without prejudice or disclaimer of the subject matter thereof.
- ✓ Claim 2, line 1, please delete "Peptide" and replace with -- A peptide --; please delete "consisting of" and replace with -- having --; and please delete "said"; and
line 2, please delete "peptide".
- ✓ Page 77, line 1, please delete "or" and replace with -- and --.
- ✓ Claim 3, line 1, please delete "Peptide" and replace with -- The peptide --; and please delete "1 or" and "said peptide";
line 8, please delete "or" and replace with -- and --.
- ✓ Claim 4, line 1, please delete "Peptide" and replace with -- The peptide --; and please delete "any of claims 1 to" and insert therefor - claim --; and please delete "said peptide"; and
line 5, please delete "or" and insert -- and --.

A, 5. (amended) The peptide [Hexadecapeptide] according to claim 3 [1 to 4 said], which is a hexadecapeptide [consisting of one of the amino acid sequences YKIVCYTWSQYREG (SEQ ID NO:1), YTSWSQYREGDGSCFP (SEQ ID NO:2), LDRFLCTHIIYSFANI (SEQ ID NO:5), THIIYSFANISNDHID (SEQ ID NO:6), PNLKTLLSVGGWNFGS (SEQ ID NO:12), QHLDFISIMTYDFHGA (SEQ ID NO:30), SPLFRGQEDASPDRFS (SEQ ID NO:34), DYAVGYMLRLGAPASK (SEQ ID NO:37), MLRLGAPASKLVMGIP (SEQ ID NO:38), YLKDRQLAGAMVWALD (SEQ ID NO:54) or LAGAMVWALDLDDFQG (SEQ ID NO:55)].

✓ Please cancel claim 6 without prejudice or disclaimer of the subject matter thereof.

~~7. (amended) A pharmaceutical [Pharmaceatical] composition comprising one or more peptides according to claim 2 [any of the claims 1 to 5[]], and a pharmaceutically [pharmaceutical] acceptable carrier.~~

Please delete Claims 8 and 9 without prejudice or disclaimer of the subject matter thereof.

Please add the following new claims:

~~-- 10. A pharmaceutical composition comprising one or more peptides according to claim 5, and a pharmaceutically acceptable carrier. --~~

~~-- 11. A test kit for use in the detection of activated autoreactive T cells, comprising one or more peptides according to claim 2. --~~

~~-- 12. A test kit for use in the detection of activated autoreactive T cells, comprising one or more peptides according to claim 5. --~~

✓
Sub C2
-- 13. A pharmaceutical composition comprising one or more peptides selected from the group consisting of peptides containing 16 to 55 amino acid residues and comprising at least one of the amino acid sequences YKLVCYYTSWSQYREG (SEQ ID NO:1), YTSWSQYREGDGSCFP (SEQ ID NO:2), LDRFLCTHIIYSFANI (SEQ ID NO:5), THIIYSFANISNDHID (SEQ ID NO:6), PNLKTLLSVGGWNFGS (SEQ ID NO:12), NTQSRRTFIKSVPPFL (SEQ ID NO:16), TFIKSVPPFLRTHGFD (SEQ ID NO:17), PPFLRTHGFDGLDLAW (SEQ ID NO:18), HGFDGLDLAWLYPGRR (SEQ ID NO:19), DLAWLYPGRRDKQHFT (SEQ ID NO:20), TIDSSYDIAKISQHL (SEQ ID NO:28), DIAKISQHLDFISIMT (SEQ ID NO:29), QHLDIFISIMTYDFHGA (SEQ ID NO:30),
EXPRESS MAIL EL087180144US

Sub C3
SPLFRGQEDASPDRFS (SEQ ID NO:34), DYAVGYMLRLGAPASK (SEQ ID NO:37),
MLRLGAPASKLVMGIP (SEQ ID NO:38), PASKLVMGIPTFGRSF (SEQ ID NO:39),
GTLAYYEICDFLRGAT (SEQ ID NO:46), EICDFLRGATVHRTL (SEQ ID NO:47),
RGATVHRTLGGQVPYA (SEQ ID NO:48), VKSKVQYLKDRQLAGA (SEQ ID NO:53),
YLKDRQLAGAMVWALD (SEQ ID NO:54), LAGAMVWALDLDDFQG (SEQ ID NO:55),
WALDLDDFQGSFCGQD (SEQ ID NO:56) or DFQGSFCGQDLRFPLT (SEQ ID
NO:57). --

Sub C3
-- 14. A pharmaceutical composition comprising one or more
peptides selected from the group consisting of peptides
containing 16 to 55 amino acid residues and comprising at least
one of the amino acid sequences YKLVCYYTSWSQYREG (SEQ ID NO:1),
YTSWSQYREGDGSCFP (SEQ ID NO:2), LDRFLCTHIIYSFANI (SEQ ID NO:5),
THIIYSFANISNDHID (SEQ ID NO:6), QHLDFISIMTYDFHGA (SEQ ID NO:30),
SPLFRGQEDASPDRFS (SEQ ID NO:34), DYAVGYMLRLGAPASK (SEQ ID NO:37),
MLRLGAPASKLVMGIP (SEQ ID NO:38), YLKDRQLAGAMVWALD (SEQ ID NO:54)
and LAGAMVWALDLDDFQG (SEQ ID NO:55). --

Sub B1
-- 15. A method of inducing systemic immunological tolerance,
comprising administering to a patient in need thereof a
pharmaceutical composition comprising one or more peptides
selected from the group consisting of peptides containing 16 to
55 amino acid residues and comprising at least one of the amino
acid sequences LVCYYTSYS (SEQ ID NO:60), FLCTHIIYS (SEQ ID
NO:61), IIYSFANIS (SEQ ID NO:62), LKTLLSVGG (SEQ ID NO:63),
FIKSVPPFL (SEQ ID NO:66), YDIAKISQH (SEQ ID NO:67), LDFISIMTY
(SEQ ID NO:68), FISIMTYDF (SEQ ID NO:69), FRGQEDASP (SEQ ID
NO:70), YAVGYMLRL (SEQ ID NO:71), MLRLGAPAS (SEQ ID NO:72),
LAYYEICDF (SEQ ID NO:73), LRGATVHRT (SEQ ID NO:74), YKLDRQLAG
(SEQ ID NO:75), LAGAMVWAL (SEQ ID NO:76), VWALDLDDF (SEQ ID
NO:77) or LDLDFFQGS (SEQ ID NO:78), and a pharmaceutically
acceptable carrier. --